Your session is about to expire
← Back to Search
Monoclonal Antibodies
Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers
Phase 1
Waitlist Available
Research Sponsored by Xencor, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Summary
This trial tests a new protein treatment, XmAb27564, in healthy men and women to see if it is safe. The treatment aims to help with autoimmune diseases by changing how the immune system works.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Single Ascending Dose - XmAb27564 Subcutaneous injection of Dose A, B, C, D, E or FExperimental Treatment1 Intervention
Group II: Single Ascending Dose - Placebo Subcutaneous injection of placeboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
XmAb27564
2021
Completed Phase 1
~50
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Xencor, Inc.Lead Sponsor
30 Previous Clinical Trials
2,604 Total Patients Enrolled
ICON Clinical ResearchIndustry Sponsor
51 Previous Clinical Trials
15,439 Total Patients Enrolled
David Liebowitz, MDStudy DirectorVice President, Clinical Development, Xencor
2 Previous Clinical Trials
352 Total Patients Enrolled
Barbara Hickingbottom, MDStudy DirectorVice President, Clinical Development, Xencor
6 Previous Clinical Trials
590 Total Patients Enrolled
Ralph Zitnik, MDStudy DirectorExecutive Medical Director, Clinical Development, Xencor
1 Previous Clinical Trials
128 Total Patients Enrolled